-
Sector Analysis
BCR-ABL Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
BCR-ABL Tests Market Report Overview The BCR-ABL Tests market size was valued at $23.5 million in 2023. The market is expected to grow at a CAGR of more than 5% during 2023-2033. Breakpoint Cluster Region - Tyrosine-Protein Kinase ABL1 fusion gene (BCR-ABL) tests are carried out to detect fusion gene mutations in patient tissue samples. The outcome may guide therapies to treat various cancers including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia (AML). BCR-ABL Tests...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olverembatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olverembatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olverembatinib in Chronic Myelocytic Leukemia (CML, Chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Constipation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Constipation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Constipation Drug Details: Risvodetinib succinate (Ikt-148009) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Dysphagia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Dysphagia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Dysphagia Drug Details: Risvodetinib succinate (Ikt-148009) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib in Pulmonary Arterial Hypertension Drug Details: Imatinib (AER-901) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dasatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dasatinib in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dasatinib in Chronic Myelocytic Leukemia (CML, Chronic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Risvodetinib Succinate in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risvodetinib Succinate in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib Succinate in Parkinson's Disease Drug Details: Risvodetinib succinate (Ikt-148009) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELVN-001 in Chronic Myelocytic Leukemia (CML, Chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olverembatinib in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olverembatinib in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Olverembatinib in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risvodetinib in Constipation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Risvodetinib in Constipation Drug Details: Risvodetinib (Ikt-148009) is under development for the treatment of Parkinson’s disease...